Created with Sketch.
33 minutes | 14 days ago
SLN Mapping in Endometrial Cancer Consensus with Andreas Obermair
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Andreas Obermair to discuss SLN mapping in endometrial cancer consensus with Andreas Obermair. Dr. Obermair is the lead author on , “Development of a surgical competency assessment tool for sentinel lymph node dissection by minimally invasive surgery for endometrial cancer” (https://ijgc.bmj.com/content/early/2021/03/31/ijgc-2020-002315), which is the Lead Article for the May 2021 issue of IJGC. Dr. Obermair is a gynaecological oncologist in Brisbane, Australia promoting surgery with proven better patient outcomes.
15 minutes | 20 days ago
Reviewing the April Issue with Alex Mutombo (French Version)
In this episode of the IJGC Podcast, Editorial Fellow Alex Mutombo reviews the contents of the April issue in French.
12 minutes | 20 days ago
Reviewing the April Issue with Nicolò Bizzarri (Italian Version)
In this episode of the IJGC Podcast, Editorial Fellow Nicolò Bizzarri discusses the contents of the April issue in Italian.
32 minutes | 22 days ago
Recurrent Ovarian Cancer: SOC-1 Trial with Rongyu Zang and Tingyan Shi
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Rongyu Zang and Tingyan Shi to discuss recurrent ovarian cancer and the SOC-1 Trial. Professor Zang is the Director of the Department of Gynecologic Oncology at Zhongshan Hospital, Fudan University in Shanghai, China. He has been specializing in gynecologic oncology, especially in clinical and translational research of advanced and recurrent ovarian cancer for the last two decades. As the founder of Shanghai Gynecologic Oncology Group (SGOG), he has been closely associated with the Gynecologic Cancer InterGroup since 2009. Professor Zang initiated several national and international multi-center randomised clinical trials, including the dose-dense EPIC trial and the SUNNY trial for advanced ovarian cancer, as well as the secondary cytoreduction trial for recurrent ovarian cancer, and so on. Dr. Shi is an Associate Professor of Oncology in the Department of Gynecologic Oncology at Zhongshan Hospital, Fudan University in Shanghai, China. She has focused on clinical and translational research in gynecologic oncology for over ten years. Dr. Shi has been trained in the Young Investigator Program of Gynecologic Cancer InterGroup, and participated in several international and national multi-center randomized clinical trials for ovarian cancer. Highlights + SOC-1 selected the candidates for secondary cytoreductive surgery with iMODEL score of 4.7 or less even after the correction by PET-CT imaging. + Secondary cytoreductive surgery favorably impacts platinum-sensitive relapsed ovarian cancer, but incomplete resection leads to the worst survival compare to no-surgery. + Accumulating treatment-free survival, as an important secondary endpoint, was added to explore the long-term survival benefit affected by a high proportion of cross-over from the no surgery froup to the surgery group when overall survival data are mature. + In both primary and recurrent settings of ovarian cancer, randomized trials are needed to confirm the survival benefit of complete surgery followed by targeting maintenance therapy.
41 minutes | 22 days ago
Legends in Gynecologic Oncology with Charles Levenback
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Charles Levenback, who is being highlighted by IJGC as a legend in gynecologic oncology. Dr. Levenback completed his fellowship at Memorial Sloan Kettering Cancer center in 1989 and then practiced at MD Anderson for 31 years. He is known as a pioneer in the development of sentinel lymph node biopsy in Gynecologic oncology, master clinician, educator, and champion for quality and safety. Highlights: + Career and professional development + Sentinel lymph node development from small case series to phase III national trial + Interest in quality improvement and patient safety
18 minutes | 23 days ago
Reviewing the April Issue with Enrique Chacon (Spanish Version)
In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discusses the contents of the April issue in Spanish.
39 minutes | 24 days ago
The Mentors Podcast
In this episode of the IJGC Podcast, Editor-in-Chief Pedro Ramirez joins Editorial Fellows Anna Collins, Irina Tsibulak, Nicolò Bizzarri, Alex Mutombo, Enrique Chacon and Arthur Hsu for an extended discussion of their experiences in gynecologic oncology, the importance of mentorship, and pathways for development in the field.
31 minutes | a month ago
ERAS Impact on Return to Treatment in Ovarian Cancer with Kevin Elias
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Kevin Elias to discuss the ERAS impact on return to treatment in ovarian cancer. Kevin Elias is an Assistant Professor of Gynecologic Oncology and Director of the Gynecologic Oncology Laboratory at Brigham and Women’s Hospital, Dana-Farber Cancer Institute, and Harvard Medical School. He is the President-Elect of ERAS USA, the American chapter of the ERAS Society. Highlights A. ERAS is associated with shorter lengths of stay and fewer complications for patients undergoing cytoreductive surgery. B. The benefits of ERAS seem to extend beyond the hospital stay, as ERAS is strongly associated with timely resumption of adjuvant chemotherapy. C. Auditing ERAS compliance is a key part of implementing an ERAS pathtway. D. ERAS reduces variation in the quality of patient care, which improves consistency in oncologic treatments and potentially outcomes.
12 minutes | a month ago
Reviewing the April Issue with Irina Tsibulak (Russian Version)
In this episode of the IJGC Podcast, Editorial Fellow Irina Tsibulak discusses the contents of the April issue in Russian.
13 minutes | a month ago
Reviewing the April Issue with Anna Collins and Irina Tsibulak (English Version)
In this episode of the IJGC Podcast, Editorial Fellows Anna Collins and Irina Tsibulak discuss the contents of the April issue.
34 minutes | a month ago
Radical Hysterectomy in Cervical Neuroendocrine Carcinoma with Michael Frumovitz
In this episode of the IJGC podcast, Editor-in-Chief, Dr. Pedro Ramirez, is joined by Dr. Michael Frumovitz to discuss radical hysterectomy in cervical neuroendocrine carcinoma. Dr. Frumovitz is an Associate Editor for IJGC and the author of the Lead Article of the April 2021 issue of IJGC, “Role of radical hysterectomy in patients with early-stage high-grade neuroendocrine cervical carcinoma: a NeCTuR study" (https://ijgc.bmj.com/content/early/2021/03/09/ijgc-2020-002213). Highlights: 1. Patients with clinical and radiologic stage I high grade neuroendocrine carcinoma of the cervix will have microscopic parametrial involvement 10% of the time 2. All patients with parametrial involvement will have other risk factors requiring postoperative radiation (positive nodes or Sedlis) 3. If a patient has negative nodes, the risk of parametrial involvement is only 3% 4. Eighty percent of recurrences will happen within first two years and 86% destined to recur will recur within 3 years
48 minutes | a month ago
IDEAL Framework Surgical Research Trials with Peter McCulloch
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Peter McCulloch to discuss the IDEAL Framework. Dr. McCulloch is Professor of Surgical Science & Practice at Oxford University. He attended medical school in Aberdeen and underwent his surgical training in Glasgow before moving to academic posts in Liverpool and then Oxford. An Upper GI cancer surgeon by background, he is the Chair of the IDEAL Collaboration, an international network of surgeons, scientists, industrial partners and patients whose goal is to improve the methodology for evaluating surgery, therapeutic devices and other complex treatments. He is also the Co-Editor-in-Chief of BMJ Surgery, Interventions, & Health Technologies (sit.bmj.com). His other major research interest is Human Factors in healthcare. He will ski anywhere, anytime, and is passionate about countering climate change. Highlights: • The IDEAL Framework & Recommendations provide an explanation of the natural history or life cycle of new procedures and devices, and a road map for how they should be evaluated at each stage in the journey. • It explains why Randomised Trials have been so difficult to do in surgery and shows that there are at least 2 preliminary steps in research (Development and Exploration) which are necessary to ensure that an RCT has a good chance of success. • IDEAL is potentially useful in surgical research at all stages, but also in device regulatory science, decisions on approving new procedures at institutions and coverage decisions • IDEAL is increasingly recognised and endorsed by major journals (Annals of Surgery, BMJ & Lancet) and professional groups (Royal College of Surgeons) and is being used by government agencies in several countries. • The IDEAL group continues to study and produce recommendations on difficult research issues such as: When is it OK NOT to do a randomised trial? How do we interpret studies using Real World Data? How should surgical robots be evaluated? And others.
27 minutes | 2 months ago
MITO16b Trial: Bevacizumab in Platinum-Sensitive Ovarian Cancer with Sandro Pignata
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Sandro Pignata to discuss the MITO16b trial. Dr. Pignata is president of the Multicenter Italian Trial in Ovarian cancer (MITO) group, member of the educational committee of ESMO, Past Chair of the European Network of Gynaecological Oncological Trial Groups (ENGOT), and member of the board of directors of the Gynecologic Cancer InterGroup (GCIG). Highlights: - The paper published on the Lancet demonstrate that bevacizumab given at recurrence is effective also in patients already treated with bevacizumab in first line. - Exploratory analysis suggest that this effect is not present in BRCA mutated patients.
15 minutes | 2 months ago
Reviewing the March Issue with Alex Mutombo (French Version)
In this episode of the IJGC Podcast, Editorial Fellow Alex Mutombo reviews the contents of the March issue in French.
19 minutes | 2 months ago
Reviewing the March Issue with Enrique Chacon (Spanish Version)
In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discusses the contents of the March issue in Spanish.
17 minutes | 2 months ago
Reviewing the March Issue with Nicolò Bizzarri (Italian Version)
In this episode of the IJGC Podcast, Editorial Fellow Nicolò Bizzarri discusses the contents of the March issue in Italian.
47 minutes | 2 months ago
International ABRAX Study with David Cibula
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. David Cibula to discuss the international ABRAX study. Dr. Cibula is the Chair of the Gynecologic Oncology Center at the General Faculty Hospital in Prague, Chair of the Central and Eastern European Gynaecologic Oncology Group (CEEGOG), as well as a Former ESGO president. Highlights: * ABRAX trial was designed to evaluate if the completion of radical hysterectomy is associated with a survival benefit in patients with early-stage cervical cancer and positive pelvic lymph node found intraoperatively. * This trial represents the largest cohort of patients managed by upfront surgery with negative lymph nodes on preoperative staging but positive lymph node involvement diagnosed during surgery. * We did not find any improvement in PFS, OS, or pelvic disease-free survival associated with radical hysterectomy, either in the whole group or in any subgroups, including patients with larger tumor size or adenocarcinomas. * The outcome of the ABRAX trial is in agreement with current international guidelines (NCCN, ESGO-ESTRO-ESP) which recommend the abandonment of further radical surgery in patients with intraoperative N1 detection.
29 minutes | 2 months ago
Conservative Management of Endometrial Cancer with Olga Novikova
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Olga Novikova to discuss the conservative management of endometrial cancer. Highlights 1) Levonorgestrel-releasing IUD containing regimens are found superior to oral medroxyprogesterone in both atypical hyperplasia and early endometrial cancer patients. 2) ART when used did not affect the recurrence rates which makes it safe to recommend to improve pregnancy rates. 3) Live births and maintenance with Levonorgestrel-releasing IUD did significantly improve disease-free survival after fertility-sparing treatment.
14 minutes | 2 months ago
Reviewing the March Issue with Irina Tsibulak (Russian Version)
In this episode of the IJGC Podcast, Editorial Fellow Irina Tsibulak discusses the contents of the March issue in Russian.
15 minutes | 2 months ago
Reviewing the March Issue with Anna Collins and Nicolò Bizzarri (English Version)
In this episode of the IJGC Podcast, Editorial Fellows Anna Collins and Nicolò Bizzarri discuss the contents of the March issue.
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2021